Clofibrate

Source: Wikipedia, the free encyclopedia.
Clofibrate
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • US: Discontinued
renal failure
ExcretionRenal, 95 to 99%
Identifiers
  • ethyl 2-(4-chlorophenoxy)-2-methylpropanoate
JSmol)
Boiling point148 °C (298 °F)
  • Clc1ccc(OC(C(=O)OCC)(C)C)cc1
  • InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3 checkY
  • Key:KNHUKKLJHYUCFP-UHFFFAOYSA-N checkY
  (verify)

Clofibrate (trade name Atromid-S) is a lipid-lowering agent used for controlling the high cholesterol and

HDL
as well.

It was patented in 1958 by Imperial Chemical Industries and approved for medical use in 1963.[1] Clofibrate was discontinued in 2002 due to adverse effects.

Complications and controversies

It can induce

SIADH, syndrome of inappropriate secretion of antidiuretic hormone ADH
(vasopressin). Clofibrate can also result in formation of cholesterol stones in the gallbladder.

The

Ischaemic Heart Disease using clofibrate to lower serum cholesterol observed excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained".[2]

References

  1. ISBN 9783527607495
    .
  2. S2CID 2473318
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Clofibrate&oldid=1127581413"